1[1]Brandes AA, Palmisano V, Pasetto LM, High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. Cancer Invest, 2001,19(1): 41-48. Review.
2[2]Henderson ES. The granulocytopenic effects of cancer chemotlterapeutic agents, in Dirnitrov NV, Nodine JH. (eds) :Drugs and Hematologic Reactions New York, Grune & Stlatton, 1974,207-221.
3[3]Eilber F, Giuliano A, Eckardt J, Adjuvant chemotherapy for osteosarcoma:a randomized prospective trial. J Clin Oncol, 1987,5(1): 20-26.
4[4]higby DJ, Wallace HJ Jr, Holland JF. Cis-diamminedichloroplatinum(NSC-119875): A phase I study. Cancer Chemother Rep, 1973,57(4):459-463.
5[5]Schepatz S. History and development of DTIC. Cancer Treat Rep, 1976,60:123-124.
6[6]Blum RH, Carter SK. Adriamycin, a new anticancer drug with significant clinical activity. Ann Intern Med, 1974,80: 249.
7[7]Goto E, Tomojiri S, Okamoto I, et al. Methotrexate poisoning with acute hepatorenal dysfunction. J Toxicol Clin Toxicol,2001,39(1): 101-104.
8[8]Aubrey DA. Massive hepatic necrosis after cyclphosphamide. Br. Med J,1970,3:588.
9[9]Von Hoff DD, Rozencweig Ⅲ, Piccart Ⅲ et al. The cardiotoxicity of anticancer agent. Semin Oncol, 1982,9: 23-33.
10[10]Suzuki K,Murtuza B,Suzuki N,et al.Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure. Circulation, 2001,18,104( 12 Suppl): I213-I217.
